This study demonstrates that Zn/Fe-MOF-derived carbon nanofibers significantly improve tetracycline degradation, suggesting enhanced wastewater treatment potential.
Plasma has become an up-and-coming advanced oxidation technology for wastewater treatment. However, its efficiency is often limited due to the lack of high-performance catalytic materials. In this study, one-dimensional carbon nanofiber precursors were first fabricated via electrospinning, followed by the in situ growth of the Zn/Fe-MOF on their surfaces. After pyrolysis at different temperatures, a series of carbon-based catalysts (FeNFC) were obtained. This new type of catalyst possesses advantages such as high porosity, a large specific surface area, and mechanical stability. Using tetracycline (TTCH) as the target pollutant, the performance of the catalyst was evaluated in the dielectric barrier discharge (DBD) system. The study showed that the addition of FeNFC significantly increased the degradation rate of TTCH in the system. Comparing different pyrolysis temperatures, at 900 °C, the comprehensive performance of the catalyst (FeNFC-900) was the best (the kinetic constant was kobs = 0.126 min−1, and the removal rate of TTCH was 91.8% within 30 min). The catalytic performance was influenced by factors such as the dosage of the catalyst, the concentration of TTCH, the power of DBD, and the initial pH. The catalytic effect of the material increased within a certain range with the increase in the catalyst dosage. The increase in TTCH concentration led to a decrease in the catalytic performance. The higher the power of the DBD, the higher the removal rate of TTCH. Moreover, when the initial pH was strongly alkaline, the catalytic effect of the catalyst was the best (kobs = 0.275 min−1, and the removal rate of TTCH was 98.7% within 30 min). Ionic interference tests demonstrated the strong resistance of FeNFC to common water matrix components, while radical quenching experiments revealed that multiple reactive species contributed to TTCH degradation. This work has broad application prospects for enhancing the efficiency of DBD systems in the removal of TTCH.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: